Core Viewpoint - The company, Xinlitai (002294), has received approval from the National Medical Products Administration for the registration of Aliskiren Indapamide Sustained-Release Tablets (Fuli'an), which are intended for the treatment of primary hypertension [1] Group 1: Product Details - The new drug contains 240mg of Aliskiren and 1.5mg of Indapamide per tablet [1] - Fuli'an is a domestically developed compound sustained-release formulation combining ARB and diuretics [1] Group 2: Strategic Positioning - The introduction of Fuli'an complements existing products such as Xinlitai, Xinchao, and Fulitai, enhancing the company's competitive edge in the cardiovascular chronic disease treatment sector [1] - The product aims to meet a broader range of clinical needs, thereby strengthening the company's market position [1]